Typhoid Fever Clinical Trials

‣ Participants must:

• Have signed/thumb-printed, voluntary, informed consent provided for them by their parent/Legally Authorized Representative (LAR) prior to performance of any study-specific procedure.

• Be a male or female infant aged 6 months (±2 weeks) or 6 weeks (+2 weeks) of age at the time of the first study vaccination.

• Have a parent/LAR, who can and will comply with the requirements of the protocol.

• Healthy as established by medical history, clinical examination, and laboratory assessment.

• Have received all routine childhood vaccinations as per the age.

• Have been born at full term (\>=37 weeks gestation) based on maternal report and additional antenatal records if available.

• Have a parent/LAR who is willing to avoid the administration of local herbal/traditional medications (including topical treatments) throughout the study period and who is willing to consult, as applicable, the study team prior to the use on other medications including over the-counter medications not supplied by the study team (except in the case of an emergency) throughout the study period.

• Have a readily identifiable place of residence within a reasonable travelling distance of the study site.

• Have a parent/LAR with a means of telephone contact.

⁃ Have a parent/LAR who is willing to avoid vaccinations not provided by the study team throughout the participant's enrollment in the study. All routine Essential Programme on Immunization (EPI) vaccines due during the study (outside those given concurrently with the study vaccines/controls) will also be administered by the study team.